fbpx Skip to main content

Supporting Life Science Means Supporting Life


Watch the full video

Return to Work

Download Our New Guide for 2021

COVID-19

Coronavirus Resource Center

 

2021 Federal Policy Priorities

Biocom California drives advocacy and public policy initiatives on behalf of the California life science industry. Our 2021 Federal Policy Priorities include Biodefense and Pandemic Research, FDA Regulatory Policy, and Patient Access to Care. Read more about priorities from every level of government here.

Read More

 

Connected by Biocom

In the world of life science, connection is the key to discovery.
Biocom connects organizations to each other so they can collaborate and work smarter together. See how we’re empowering members with novel resources and networks so they can grow faster and work efficiently.

Learn More

EXPERIENCE THE SAVINGS

Take advantage of 30+ RFP-vetted life science-related contracts.

Trending

Return to Work Guide 2.0
Learn More

Biocom has released our updated Return to Work Guide for 2021

DEI Report
Learn More

View the state of Diversity, Equity, and Inclusion across CA life science companies

Member Spotlights
Learn More

Learn more about Biocom members making a difference

2021 GPC
Learn More

Register for our virtual 2021 Global Partnering Conference

“I have had the opportunity to give presentations to VCs and Pharma Venture Funds at several Venture Day events. These experiences have been very helpful with respect to meeting investors from outside the San Diego area and also for valuable feedback. This is an important Biocom program!”
Michael J. Newman, CEO, Decoy Biosystems
“The LSYL (Life Science Young Leaders) series is a terrific idea. It’s just easier to make meaningful connections among contemporaries and this series is a great platform for that. I look forward to the next one.”
Brendan McCarthy, Attorney, Gunderson Dettmer Stough Villeneuve Franklin & Hachigan
“I was impressed with Biocom’s DeviceFest & Digital Health Conference on August 29th, 2018. The conference had a balance view of content and discussion time with industry experts, which allowed us to have deeper introductory meetings, which will lead to deeper relationships with experts from all over North America. Great job by the planning committee and the management of Biocom.”
Dipak Shah, Board Member, Obsidio Therapeutics, Inc.

CHOOSE YOUR NEWS

Subscribe to Biocom newsletters tailored to your interests.